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The Relationship between Normal Serum Uric Acid and 
Nonalcoholic Fatty Liver Disease
The objective of the present study was to determine the relationship between serum uric 
acid (SUA) level and the presence of nonalcoholic fatty liver disease (NAFLD). We analyzed 
data of 9,019 Koreans who visited a health check up center. The SUA levels of all of these 
subjects were within the normal range. The participants were divided into 4 groups 
according to the quartiles of the SUA levels for both sexes. Hepatic steatosis was diagnosed 
on the basis of ultrasonographic findings. Multivariate logistic regression modeling was 
performed across the SUA quartiles. The presence of NAFLD and metabolic abnormalities 
were found significantly in subjects with high-normal SUA levels. After adjustment for 
age, metabolic components, and the liver-function test, the adjusted odds ratio (OR, 95% 
CIs) for the presence of NAFLD in the subjects with the highest SUA level was 1.46 (1.17-
1.82) for men and 2.13 (1.42-3.18) for women, as compared to the subjects with the 
lowest SUA level. Our results suggest that increased SUA concentrations, even within the 
normal range, are independently associated with the presence of NAFLD.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is characterized by 
fatty deposition in the hepatocytes of patients with minimal or 
no alcohol intake. As obesity and metabolic syndrome (MS) have 
become epidemic, NAFLD has become the most frequent type 
of liver disease (1). There are several possible reasons for fat ac-
cumulation in the liver. Metabolic derangement based on insu-
lin resistance is the most acknowledged cause of fat accumula-
tion, and is commonly associated with dyslipidemia, type 2 dia-
betes mellitus, and central obesity (2-5). Therefore, NAFLD has 
been considered as the hepatic manifestation of MS. 
  Serum uric acid (SUA) is the major end product of purine 
metabolism in humans; and the level of SUA is rigorously con-
trolled by the balance between uric acid production and excre-
tion (6). A number of previous studies have reported the rela-
tionship between hyperuricemia and various cardiovascular 
diseases and their risk factors, including MS. According to the 
earlier studies, not only frank hyperuricemia but also SUA lev-
els almost within the normal range showed a positive correla-
tion with MS (7). 
  Recent studies have shown that SUA level was significantly 
associated with NAFLD and elevated SUA level was an indepen-
dent risk factor for NAFLD (8-10). In previous studies, research-
ers examined subjects with overt hyperuricemia. We hypothe-
size that there are similar associations within the normal range 
of SUA. To the best of our knowledge, no study has been per-
formed so far to investigate the association of the normal level 
of SUA with NAFLD. Therefore, we explored the relationship 
between the presence of NAFLD and normal SUA levels by a 
cross-sectional study.
 
MATERIALS AND METHODS
Study population
In this study, 13,007 subjects older than 20 yr were screened for 
inclusion. All of these subjects voluntarily visited the health pro-
motion center of Dongguk University Ilsan Hospital, Korea, for 
annual checkups between June 2007 and July 2009. The aim of 
the screening was to detect any metabolic diseases (such as di-
abetes, dyslipidemia) and cancers. The analysis for the present 
study was limited to 12,839 subjects who underwent abdominal 
ultrasonography, whose medical records were retrospectively 
reviewed. The subjects were considered eligible to participate 
in this study if they met all of the following criteria: an SUA level 
of ≤ 7.2 mg/dL for men and ≤ 5.7 mg/dL for women (the upper 
reference limit in our laboratory), a creatinine level of < 1.4 mg/
dL (to rule out renal insufficiency), an alanine aminotransferase 
(ALT) level of < 70 U/L and a γ-glutamyltransferase (GGT) level 
of < 70 mg/dL (for eliminating the possibility of any other liver 
diseases), a thyroid stimulating hormone (TSH) level of 0.27-4.2 
μIU/mL, a free thyroxine (free T4) level of 0.93-1.7 ng/dL, and Hwang I-C, et al.  •  Normal Serum Uric Acid and NAFLD
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negative tests for hepatitis B antigen and hepatitis C antibodies. 
Subjects meeting any of the following criteria were excluded 
from the study: any missing covariate information; those with 
an alcohol consumption of greater than 20 g/day for men and 
10 g/day for women; those with a history of other known causes 
of chronic liver disease, such as viral hepatitis or autoimmune 
hepatitis, and on hepatotoxic medications; and those with a his-
tory of cancer, respiratory ailments, renal diseases, endocrine 
disorder, hepatobiliary diseases, or gout. Finally, 9,019 subjects 
(4,632 men and 4,387 women) were included in the final analy-
sis of this study. 
Clinical examination
All medical examinations were performed by trained staffs by a 
standardized procedure. Data on Health Habits Inventory and 
past or present medical history were obtained through a ques-
tionnaire survey. The questions related to alcohol intake were 
as follows: the type of alcoholic beverage consumed, frequency 
of alcohol consumption on a weekly basis, and amount of alco-
hol consumed daily. Smoking status was categorized into non-/
ex-/current smokers. The participants were also inquired about 
the type and frequency of physical activity that they performed 
on a weekly basis. A regular exerciser was defined as a person 
who engaged in physical activities for more than 20 min per ses-
sion, 3 times a week. Height and weight were measured using 
an automatic digital stadiometer (GL-150, G-TECH Internation-
al Co., Uijungbu, Korea), with the subjects dressed in a light gown 
and standing barefoot. Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared. Ac-
cording to the World Health Organization (WHO) protocol (11), 
waist circumference (WC) was measured using a non-stretch-
able standard tape. Blood pressure was measured using the au-
tomatic clinical blood pressure monitor (TM-2655, A&D Co., 
Tokyo, Japan) while the subjects were seated comfortably after 
a rest period of at least 10 min. The participants were instructed 
to refrain from drinking coffee, smoking cigarettes, or engaging 
in strenuous exercise for 30 min before their blood pressures 
were measured. 
Laboratory measurements
All blood samples were obtained from the antecubital vein in the 
morning after overnight fast and stored in plastic tubes. The sam-
ples were subsequently analyzed using an automatic chemical 
analyzer at a laboratory in Dongguk University Ilsan Hospital. 
Detection of hepatic steatosis
In this study, hepatic steatosis was diagnosed by ultrasonogra-
phy (Philips iu-22 Ultrasound Machine; Philips Medical Sys-
tems, Bothell, WA, USA) according to the conventional criteria 
(i.e., evidence of diffuse hyperechogenicity of liver relative to 
kidneys, ultrasound beam attenuation, and poor visualization 
of intrahepatic structure), based on the characteristic echo pat-
terns (2). The ultrasonography was performed by 5 experienced 
radiologists who did not have access to the subjects’ clinical or 
laboratory test findings and were unaware of the goal of the study. 
They diagnosed hepatic steatosis according to identical criteria; 
therefore, we assumed the intraobserver variability among them 
to be minimal. NAFLD in the patients was defined as having 
any degree of hepatic steatosis on abdominal ultrasonographic 
findings, with the aforementioned inclusion/exclusion criteria 
of alcohol consumption, viral, or autoimmune liver diseases. 
Definition of metabolic syndrome (MS)
The diagnosis of MS was made on the basis of the revised Nation-
al Cholesterol Education Program (NCEP) criteria, proposed by 
the American Heart Association/National Heart, Lung, and Blood 
Institute (AHA/NHLBI) (12). The WC cutoff was defined accord-
ing to central obesity in Koreans (13). Therefore, MS was defined 
by the presence of any 3 or more of the following risk factors: 1) 
central obesity, with an WC ≥ 90 cm for men and ≥ 85 cm for 
women; 2) hypertriglyceridemia, with a triglyceride level of ≥ 150 
mg/dL; 3) low high density lipoprotein cholesterol (HDL-C), 
with an HDL-C < 40 mg/dL for men and < 50 mg/dL for wom-
en; 4) elevated blood pressure, with a blood pressure ≥130/85 
mmHg or antihypertensive medication; and 5) elevated fasting 
plasma glucose (FPG) level (FPG ≥ 100 mg/dL) or antidiabetic 
medication (insulin or oral agents).
Statistical analysis
Statistical analyses were performed using the Statistical Package 
for Social Sciences (SPSS) software package version 16.02 for 
Windows (SPSS Inc., Chicago, IL, USA). For the demographic 
and biochemical characteristics, the continuous variables were 
expressed as mean and standard deviation (SD), whereas the 
categorical variables were summarized into frequency and per-
centage. Independent 2-sample t-tests and chi-square-tests 
were used for the investigation of any association with NAFLD. 
The odds ratio (OR) and 95% confidence interval (CI) for the 
presence of NAFLD, according to the SUA quartiles and in the 
case of it being considered as a continuous value, were calculat-
ed after adjusting for confounding variables, using multivariate 
logistic regression models. The confounding variables were age, 
smoking habit, exercise status, BMI, blood pressure, FPG, total 
cholesterol, triglyceride, HDL-C, aspartate aminotransferase, 
ALT, and GGT. The association between MS and the SUA quar-
tiles were examined using chi-square-tests as well as linear-by-
linear association tests. All statistical tests were 2-sided and a P 
< 0.05 was recognized as the statistical significance level.
Ethics statement
This study was approved by the institutional review board (IRB) 
of Dongguk University Ilsan Hospital, Goyang, Korea. Informed Hwang I-C, et al.  •  Normal Serum Uric Acid and NAFLD
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consent from the participants was waived by the IRB.
RESULTS
Table 1 presents the demographic and biochemical characteris-
tics of the 9,019 subjects according to their NAFLD status. Among 
them, 2,124 (23.6%) subjects met the diagnostic criteria for NA-
FLD. The mean age and proportion of men was higher in the 
NAFLD group, and the group showed a high obesity index, more 
deranged metabolic profile, and elevated results of the liver-func-
tion test. In particular, significantly higher SUA levels were ob-
served in the subjects with NAFLD than in those without NAFLD. 
  Fig. 1 shows that the prevalence rate of MS and components 
of MS increased with an increment in the SUA level. The excep-
tion was the relationship between an elevated FPG and the SUA 
level. The proportions of MS in each quartile were 9.7%, 11.5%, 
14.2%, and 20.9%, respectively. 
  The prevalences of each component of MS, MS and NAFLD 
are shown in Table 2. MS was identified in 1,289 subjects (14.3%; 
876 men and 413 women). The percentages of MS in subjects in 
the fourth and other quartiles of SUA level were 23.1% and 17.5% 
for men, and 18.8% and 6.2% for women, respectively. The per-
centages of NAFLD were 44.2% and 31.7% for men, and 22.3% 
and 7.9% for women, respectively. The presence of NAFLD and 
MS (including each component of MS) were found significant 
in the subjects with the highest SUA quartile. There was no sig-
nificant association between an elevated FPG and the highest 
SUA quartile in men.
  Table 3 shows the risk of NAFLD according to the SUA quar-
tiles. After adjustment for age, components of MS and the liver-
function test, the adjusted OR (95% CI) for the presence of NA-
FLD in the subjects with the highest SUA level was 1.46 (1.17-
1.82) for men and 2.13 (1.42-3.18) for women, as compared to 
the subjects with the lowest SUA level. It was also significant for 
both genders in the case of the SUA level being considered as a 
continuous value.
 
DISCUSSION
Our findings proved that SUA concentrations, even within the 
normal range, were significantly associated with the presence 
of NAFLD. It is remarkable that those subjects of upper normal 
SUA range showed not only a more deranged metabolic profile, 
but were also at a higher risk for NAFLD. The results remained 
significant after adjustment for possible confounders. Therefore, 
Table 1. Demographic and biochemical characteristics of the subjects according to 
their nonalcoholic fatty liver disease (NAFLD) status
With NAFLD  
(n = 2,124)
Without NAFLD  
(n = 6,895)
P value
Age (yr) 44.0 (13.0) 41.0 (11.0) < 0.001
Gender (men, %) 1,613 (75.9) 3,019 (43.8) < 0.001
Current smokers (%) 644 (30.3) 1,382 (20.0) < 0.001
Regular exercisers (%) 845 (39.8) 2,587 (37.4) 0.056
Body mass index (kg/m
2) 25.3 (3.6) 22.1 (3.7) < 0.001
Waist circumference (cm)  86.9 (7.1) 76.3 (8.5) < 0.001
Systolic blood pressure (mmHg) 124.0 (19.0) 114.0 (19.0) < 0.001
Diastolic blood pressure (mmHg) 82.3 (11.0) 75.2 (11.5) < 0.001
FPG (mg/dL) 95.0 (15.0) 88.0 (11.0) < 0.001
Total cholesterol (mg/dL) 202.0 (50.0) 187.0 (44.0) < 0.001
Triglyceride (mg/dL) 159.0 (111.0) 94.0 (61.0) < 0.001
HDL cholesterol (mg/dL) 46.0 (14.0) 57.0 (19.0) < 0.001
Aspartate aminotransferase (IU/L) 23.0 (9.0) 19.0 (7.0) < 0.001
Alanine aminotransferase (IU/L) 27.0 (18.0) 15.0 (9.0) < 0.001
γ-Glutamyltransferase (IU/L) 30.0 (25.0) 16.0 (14.0) < 0.001
Uric acid (mg/dL) 5.6 (1.5) 4.6 (1.7) < 0.001
Data are presented as the mean (SD) or number (percentage). P values were calculated 
using an independent 2-sample t-test. FPG, fasting plasma glucose; HDL, high density 
lipoprotein.
Fig. 1. Prevalences of metabolic syndrome (MS) and each component of MS according to the serum uric acid (SUA) quartiles. Metabolic syndrome was defined as having 3 or 
more of the following criteria: an waist circumference of ≥ 90 cm for men and ≥ 85 cm for women; a triglyceride level of ≥ 150 mg/dL; HDL cholesterol < 40 mg/dL for men 
and < 50 mg/dL for women; blood pressure ≥ 130/85 mmHg or receiving antihypertensive drugs; fasting plasma glucose (FPG) ≥ 100 mg/dL or receiving antidiabetic medication. 
*P for trend < 0.05.
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we suggest that physicians should pay attention to the possibil-
ity of NAFLD in patients with upper range of normal SUA levels. 
To the best of our knowledge, this is the first study that demon-
strates the relationship between normal SUA level and NAFLD. 
  The results of previous studies are consistent with those of 
our study. Some researchers demonstrated that SUA level is an 
independent risk factor for NAFLD in healthy adults and recom-
mended it as an additional measure in assessment of the risk 
for NAFLD (9, 10). Their results are in overall accordance with 
the results of our study, but there are a few differences. First, the 
distribution of SUA concentration was not confined to the refer-
ence range. Although the 75% interquartile range (IQR) in their 
studies was equivalent to the upper normal SUA range in this 
study, however, multivariate analysis was not performed within 
the lower quartiles (Q1-Q3) in their studies. Lee et al. could not 
show the positive correlation between SUA (Q1-Q3) levels and 
the risk of NAFLD in women with a multivariate logistic regres-
sion analysis model. Second, our data excluded possible con-
founders, such as serum creatinine and ALT levels. Hyperurice-
mia can be caused by either the overproduction or underexcre-
tion of uric acid, and 85%-90% of hyperuricemic patients in the 
general population show underexcretion of uric acid. ALT ac-
tivity is known to be significantly correlated with increased fat 
accumulation in the liver (14), and NAFLD is the most common 
cause for unexplained persistent elevation of ALT levels (15). In 
addition, a small elevation of ALT levels (less than twice the nor-
mal value) may be of no clinical importance if the causes of 
chronically elevated aminotransferase levels, including hepatic 
steatosis, have been ruled out (16).
  Several epidemiologic studies have shown that elevated SUA 
levels, including those within the normal range, could predict the 
increased risk of cardiovascular events (17, 18) or renal impair-
ment (19). The most marked increase in cardiovascular death 
in healthy middle-aged men occurred at the SUA level of 5.21 
mg/dL, and the risk of stroke in patients with type 2 diabetes 
increased steeply at the SUA median value of 4.96 mg/dL. The 
terms “normal range” or “reference range” have been used in 
similar circumstances, and are based on the values in apparent-
ly normal individuals from a certain area. The “reference range” 
can be altered depending on certain conditions. As a common 
Table 2. Comparisons for the prevalence of each component of metabolic syndrome and nonalcoholic fatty liver disease (NAFLD) between the high-normal serum uric acid 
(SUA) quartile and other quartiles
Uric acid quartiles in men (mg/dL)  Uric acid quartiles in women (mg/dL) 
Quartiles 1-3 (< 6.4) Quartile 4 (≥ 6.4) P value Quartiles 1-3 (< 4.6) Quartile 4 (≥ 4.6) P value
Abdominal obesity 616 (17.8) 309 (26.5) < 0.001 242 (7.4) 225 (19.8) < 0.001
Hypertriglyceridemia  1,227 (35.4) 532 (45.5) < 0.001 344 (10.6) 254 (22.4) < 0.001
Low HDL cholesterol 582 (16.8) 232 (19.8) 0.019 629 (19.3) 349 (30.7) < 0.001
High blood pressure 1,387 (40.1) 516 (44.1) 0.015 613 (18.9) 365 (32.1) < 0.001
Elevated FPG 752 (21.7) 223 (19.1) 0.054 288 (8.9) 167 (14.7) < 0.001
Metabolic syndrome 606 (17.5) 270 (23.1) < 0.001 200 (6.2) 213 (18.8) < 0.001
NAFLD 1,096 (31.7) 517 (44.2) < 0.001 258 (7.9) 253 (22.3) < 0.001
Data are presented as number (percentage). P values were calculated using the χ2 test. Metabolic syndrome was defined as fulfillment of 3 or more of the following criteria: an 
waist circumference of ≥ 90 cm for men and ≥ 85 cm for women; a triglyceride level of ≥ 150 mg/dL; HDL cholesterol of < 40 mg/dL for men and < 50 mg/dL for women; 
blood pressure ≥ 130/85 mmHg or receiving antihypertensive drugs; fasting plasma glucose of ≥ 100 mg/dL or receiving antidiabetic medication. Based on the level of SUA, 
the 4 categories were as follows: quartile 1, < 5.1 mg/dL for men and < 3.1 mg/dL for women; quartile 2, 5.1-5.6 mg/dL for men and 3.5-3.9 mg/dL for women; quartile 3, 
5.7-6.3 mg/dL for men and 4.0-4.5 mg/dL for women; quartile 4, 6.4-7.2 mg/dL for men and 4.6-5.7 mg/dL for women. HDL, high-density lipoprotein; FPG, fasting plasma 
glucose.
Table 3. Odds ratio and 95% confidence intervals for the presence of nonalcoholic fatty liver disease (NAFLD) according to the serum uric acid (SUA) quartiles and in the case 
of being considered as a continuous value in men and women
Gender SUA (mg/dL)
Odds ratio (95% confidence interval)
Unadjusted Model 1* Model 2
† Model 3
‡
Men Quartile 1 (< 5.1)
Quartile 2 (5.1-5.6)
Quartile 3 (5.7-6.3)
Quartile 4 (6.4-7.2)
As a continuous value
1
1.18 (0.98-1.43)
1.56 (1.32-1.86)
2.14 (1.79-2.55)
1.41 (1.32-1.52)
1
1.21 (1.00-1.45)
1.62 (1.36-1.93)
2.24 (1.88-2.67)
1.44 (1.34-1.55)
1
1.13 (0.91-1.41)
1.34 (1.09-1.64)
1.54 (1.25-1.89)
1.22 (1.13-1.33)
1
1.09 (0.87-1.37)
1.34 (1.08-1.66)
1.46 (1.17-1.82)
1.21 (1.11-1.32)
Women Quartile 1 (< 3.5)
Quartile 2 (3.5-3.9)
Quartile 3 (4.0-4.5)
Quartile 4 (4.6-5.7)
As a continuous value
1
1.36 (0.92-2.00)
2.51 (1.77-3.55)
5.59 (4.00-7.80)
2.61 (2.27-3.00)
1
1.34 (0.90-1.98)
2.49 (1.74-3.55)
4.92 (3.50-6.93)
2.39 (2.07-2.76)
1
1.06 (0.69-1.64)
1.67 (1.13-2.47)
2.29 (1.57-3.35)
1.59 (1.35-1.87)
1
0.96 (0.61-1.52)
1.73 (1.14-2.61)
2.13 (1.42-3.18)
1.53 (1.29-1.82)
P values were calculated using multivariate logistic regression analysis. *Adjusted for age; 
†Adjusted for the variable in model 1 plus smoking status, regular exercise, body 
mass index, blood pressure, fasting plasma glucose, total cholesterol, triglyceride, and HDL cholesterol; 
‡Adjusted for the variables in model 2 plus aspartate aminotransferase, 
alanine aminotransferase, and γ-glutamyltransferase.Hwang I-C, et al.  •  Normal Serum Uric Acid and NAFLD
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example, the cutoff value for central obesity has been changed 
according to the times as well as the gender or ethnicity. This 
was based on the simple result that the OR for the having 2 or 
more components of metabolic syndrome increased abruptly 
at a specific point, which would be flexible at any time (13). We 
documented the independent associations between SUA con-
centrations within the normal range and the presence of NAFLD, 
and a higher prevalence of MS was also found in those subjects 
with high-normal SUA levels. We are of the opinion that elevat-
ed SUA, even within the normal range, can trigger the clinical 
suspicion of NAFLD and investigation for a potential coexistence 
of NAFLD should be carried out. 
  The most plausible explanation for the association between 
SUA and NAFLD, which has been inferred from the current un-
derstanding of the progression of NAFLD (20), would be the ‘2-
hit’ theory. Fat accumulation in the liver is the first “hit”, which 
makes the hepatocytes more vulnerable to further damage due 
to certain triggers, such as insulin resistance, inflammation, ex-
cess alcohol consumption, and obesity. In this process, insulin 
resistance plays a central role in the vicious cycle, which pro-
motes lipolysis of peripheral adipose tissue and increases free 
fatty acid influx into the liver. This insulin resistance leads to hy-
perinsulinemia, which increases uric acid synthesis and reduc-
es the renal excretion of uric acid (21, 22). Nakagawa et al. (23) 
reported that a SUA level above 5.5 mg/dL independently pre-
dicted the development of hyperinsulinemia in nondiabetic 
patients with first myocardial infarction. The processes involved 
in the second “hit” are thought to be oxidative stress, subsequent 
lipid peroxidation, and an inflammatory response. SUA has been 
proved to be proinflammtory and an increased SUA level reflects 
the rate of cell turnover, which itself may be a part of the inflam-
matory process (24). Uric acid stimulates the synthesis of mono-
cyte chemoattractant protein-1 and increases interleukin (IL)-6 
and tumor necrosis factor-alpha (TNF-α) (25). Recently, Rug-
giero et al. (26) confirmed a positive association between SUA 
and several inflammatory markers within the normal SUA range 
(2-7.5 mg/dL in men and 2-5.7 mg/dL in women) in subjects. 
The significant association with SUA between the high-normal 
range and NAFLD in our study population supports the concept 
that the 2 components shared the mechanisms of hyperinsu-
linemia and the inflammatory process, from the normal level of 
SUA. 
  There are several limitations to our study. First, we could not 
answer the question whether high-normal SUA level is a cause 
or an effect of NAFLD with this cross-sectional design. Further 
research is needed to clarify their interrelationship. Second, po-
tential confounders of the SUA level, such as dietary pattern and 
the use of diuretics/β-blockers, were not considered. Third, we 
could not perform the gold standard liver biopsy for diagnosing 
hepatic steatosis. Another limitation was that we did not test in-
traobserver variability between the radiologists who performed 
ultrasonography. Nevertheless, ultrasonography is the most 
widely used modality in epidemiological studies for NAFLD, 
not only because it is non-invasive and easily available but also 
because its accuracy in detecting hepatic steatosis is acceptable 
(27). Finally, generalization of the present results should be con-
sidered with caution. Because the study subjects were visitors 
to a health promotion center, so they might be more health-con-
scious and wealthier than the general populations studied in 
community-based studies. 
  In conclusion, in the present study, increased uric acid con-
centrations, even within the normal range, were independently 
associated with the presence of NAFLD. This finding indicates 
that Korean adults with a high-normal uric acid level would be 
regarded as a group at an increased risk for NAFLD.
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Disease
In-Cheol Hwang, Sang-Yeon Suh, Ah-Ram Suh, and Hong-Yup Ahn
Abnormally high level of uric acid in serum (hyperuricemia) is associated with nonalcoholic fatty liver disease (NAFLD). However, it 
is not known whether there is a relation between NAFLD and serum uric acid (SUA) within normal range. We analyzed data of 
9,019 Koreans who visited a health check up center. The participants were within normal SUA range and categorized according to 
the SUA quartiles. Fatty liver was diagnosed using an ultrasonography. The NAFLD and metabolic abnormalities were found 
significantly higher in subjects with high-normal SUA levels. After adjustment for possible confounders using multivariate logistic 
regression, the adjusted odds ratio for the presence of NAFLD in the subjects with the highest SUA level was 1.46 (95% confidence 
interval (CI) 1.17-1.82) for men and 2.13 (95% CI 1.42-3.18) for women, as compared to the subjects with the lowest SUA level. 
We suggest that increased SUA concentrations, even within the normal range, are independently associated with NAFLD.